Tagged with GEN

Ecuador Pablo Ledesma del Pozo, managing director at PharmaBrand, discusses the company’s ambition to equal the business model of a multinational companies in the foreseeable future by commercializing their products as well as opening fully-integrated affiliates in neighboring countries, such as Chile, Peru, Bolivia and Central American countries. Pablo, you have…

Canada Heather Chalmers, vice president and general manager of GE Healthcare Canada, shares the company’s increasing focus on incorporating applied intelligence and digital analytics in its portfolio of innovative solutions, and how these can have significant effects on patient outcomes as well as the whole healthcare system. She further highlights the…

UK Tim de Gavre, country head of Sandoz UK, discusses the role of biosimilars in driving innovation, the threats and opportunities of Brexit to the biosimilars industry, and how Sandoz partners with the NHS. In addition to your role at Sandoz, you are also one of the founding members of the…

Poland As east area director for the vast CEE market, Pawel Mazur explains how Accord Healthcare has gone from strength to strength in Poland, with the intention of becoming a top five generics company in the country by 2021. He also touches on the importance of a high-performing team, the exciting…

Estonia Riho Tapfer, director of the Association of Pharmaceutical Manufacturers of Estonia (APME), explains that a modern healthcare system and better medical care will require the widespread adoption of electronic health information which, in turn, allows for changes in important areas including prevention and more personalized care tailored specifically to a patient’s genetic…

Baltics Roland Lepik, cluster head Baltics at Sandoz, discusses the company’s strategy that has allowed it to rank number one in the Estonian market along with the importance of ever-closer collaboration with key stakeholders to enhance the uptake of biosimilars. Roland, prior to joining Sandoz as Cluster Head Baltics you were…

India Murtaza Khorakiwala, managing director of Wockhardt, discusses the company’s vast international expertise in the manufacturing of pharmaceuticals and biopharmaceutical formulations in their 12 US FDA, UK MHRA and EMA compliant manufacturing facilities in India, as well as the out-licensing of its products into other regions to capture and penetrate new…

India As managing director of India’s fifth largest pharmaceutical company, Zydus Cadila’s Sharvil Patel shares his insights on his impressive internationalization strategy with a special focus on the US where Zydus recently received permission to conduct Phase II clinical studies of Lipaglyn, the first drug to treat patients with nonalcoholic steatohepatitis…

Estonia Kristin Raudsepp, director general of Estonia’s drug regulator – the State Agency of Medicines – discusses her organization’s mandate, current priorities, and reactiveness to the pervading trends in international regulation. Can you introduce the State Agency of Medicines of Estonia and its mandate to our international readers? “Despite of the…

Baltics Juris Hmelnickis PhD, Chairman of the Board of JSC Kalceks, explains the story and the evolution of the company in Latvia, its key products in the CNS therapeutic area and how they were able to piggyback on the established footprint of their mother company, JSC Grindeks, to launch products in…

Poland Markus Sieger, CEO of Polpharma, outlines his global strategy for the company, focused on OTC and CHC, internationalization and a strong R&D strategy to push forward biosimilars. Furthermore, he highlights Polpharma’s digital approach and the company’s long-term vision for sustained success across the region.   Our international markets are growing…

Baltics Janis Meiksans, general manager at TEVA Baltics, explains how the base of the company’s success is what they call ‘generic evangelism’ and how from being a marketing and distribution organization in the region, they successfully managed to rank number one pharmaceutical company by sales. Janis, can you talk our international…